BackZhejiang Ausun Pharmaceutical , Ltd. Overview

Zhejiang Ausun Pharmaceutical , Ltd. Current Assets

Latest current assets for 603229.SS: $1.8B.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$1.78B
↓ 4.36% YoYΔ $-81.09M vs prior year quarter

Peer trimmed avg / median

Loading

Zhejiang Ausun Pharmaceutical , Ltd. Current Assets History

Loading

Zhejiang Ausun Pharmaceutical , Ltd. vs. peers: Current Assets Comparison

Loading

Zhejiang Ausun Pharmaceutical , Ltd. Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Zhejiang Ausun Pharmaceutical , Ltd. (603229.SS) FAQ

Zhejiang Ausun Pharmaceutical , Ltd. posts a current assets of $1.8B as of June 2026. That compares with $1.9B in the prior-year period — down 4.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Zhejiang Ausun Pharmaceutical , Ltd.'s current assets was $1.9B. The latest reading is $1.8B — a 4.4% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Zhejiang Ausun Pharmaceutical , Ltd.'s financial statement story. At $1.8B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 603229.SS's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Zhejiang Ausun Pharmaceutical , Ltd.'s other metric pages and overview cover the third.

Judging Zhejiang Ausun Pharmaceutical , Ltd. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $1.8B here, then scan peer and history charts to see if the gap is persistent.